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To explore associations between exposures to medicines prescribed for asthma and their
discontinuation in pregnancy and preterm birth [<37 or <32 weeks], SGA [<10th and <3rd
centiles], and breastfeeding at 6–8 weeks.
Methods
Design. A population-based cohort study.
Setting. The Secure Anonymised Information Linkage [SAIL] databank in Wales, linking
maternal primary care data with infant outcomes.
Population. 107,573, 105,331, and 38,725 infants born 2000–2010 with information on
premature birth, SGA and breastfeeding respectively, after exclusions.
Exposures. maternal prescriptions for asthma medicines or their discontinuation in
pregnancy.
Methods. Odds ratios for adverse pregnancy outcomes were calculated for the exposed
versus the unexposed population, adjusted for smoking, parity, age and socio-economic status.
Results
Prescriptions for asthma, whether continued or discontinued during pregnancy, were asso-
ciated with birth at<32 weeks’ gestation, SGA <10th centile, and no breastfeeding (aOR
1.33 [1.10–1.61], 1.10 [1.03–1.18], 0.93 [0.87–1.01]). Discontinuation of asthma medicines
in pregnancy was associated with birth at<37 weeks’ and <32 weeks’ gestation (aOR 1.22
[1.06–1.41], 1.53 [1.11–2.10]). All medicines examined, except ICS and SABA prescribed
alone, were associated with SGA <10th centile.
Conclusions
Prescription of asthma medicines before or during pregnancy was associated with higher
prevalence of adverse perinatal outcomes, particularly if prescriptions were discontinued
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during pregnancy. Women discontinuing medicines during pregnancy could be identified
from prescription records. The impact of targeting close monitoring and breastfeeding sup-
port warrants exploration.
Introduction
The prevalence of asthma in pregnancy has increased worldwide [1–3]. Approximately 9%
of pregnant women in the UK are prescribed medicines for asthma, more than elsewhere in
Europe [4]. However, there is no consensus on the effect of asthma or prescription of asthma
medicines on perinatal outcomes. While older [5] and smaller [6, 7] studies were reassuring,
asthma [3, 8] accompanied by symptoms [5, 9] or suboptimal spirometry recordings [10]
has been associated with growth restriction [small for gestational age [SGA]]. Premature
birth is associated with asthma diagnosis in some studies [11, 12], but not others [8]. Active
management of asthma may reduce premature birth [13], and uncontrolled asthma increases
the risk of adverse perinatal outcomes [3], but there is less information on medicines pre-
scribed for asthma. Few RCTs have examined the impact of asthma medicines in pregnancy
on perinatal outcomes, and no differences were seen in any of the small trials located [14].
Short-Acting Beta Agonists [SABA] have not been associated with growth restriction or pre-
mature birth, although studies have relatively low numbers [15], and there is no consensus
on the impact of Long-Acting Beta Agonists [LABA] [15–17]. There are few differences
between medicines within each class [18]. Up to 50% pregnant women discontinue asthma
medicines, often without professional advice, frequently worsening asthma and outcomes
[1, 9, 14].
Medicines prescribed for asthma cross the placenta and enter breastmilk [6, 13]. Prescrip-
tion of asthma medicines in early pregnancy is associated with increased prevalence of con-
genital anomalies [aOR 1.20, 1.08–1.34], but the effects of asthma could not be separated
from those of its treatment [19]. Premature birth, SGA, and suboptimum breastfeeding
threaten survival, developmental potential and ill-health from non-communicable disease in
developed and developing countries [20], and the effects of medicines and their discontinua-
tion on the range of pregnancy outcomes, including lactation, need to be considered
together.
UK guidelines recommend that women prescribed asthma medicines breastfeed, and offer
reassurance on oral corticosteroids [5]. Few studies reporting medicines’ use and breastfeeding
were located, all relatively small, and suggesting that breastfeeding rates were lower if medi-
cines were prescribed. None considered medicines for asthma [21]. Despite the known health
and economic benefits of breastfeeding [22, 23], we were unable to locate reports of the impact
of prescription medicines on the prevalence of breastfeeding amongst women with asthma.
To identify women likely to benefit from additional care, and target support, we aimed to
explore any associations between prescriptions for asthma medicines during pregnancy, or
their discontinuation, and the range of perinatal outcomes that matter to women [prematurity,
SGA, and, for the first time, breastfeeding at 6–8 weeks, full or partial].
Methods
A population-based cohort was built from prospectively collected routine NHS data and ana-
lysed retrospectively [24]. We explored association, rather than causality, as there was no
randomisation.
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Ethics
The Secure Anonymised Information Linkage [SAIL] Databank Information Governance
Review Panel [IGRP] approved the study on behalf of the National Research Ethics Service,
Wales on 24th March 2011. Data were irrevocably anonymised and obtained with permission
of the relevant Caldicott Guardian and Data Protection Officer.
Setting
Data were extracted from existing routinely collected data in SAIL, housed in Swansea Univer-
sity https://saildatabank.com/faq/ [25–27]. By 2014, ~40% of general practices had agreed to
share data with SAIL, without payment. Women in the included population were slightly less
deprived and older than the rest of Wales [27]. Using unique personal identifiers, which
remained undisclosed to researchers to ensure anonymity, we linked primary care records,
including prescriptions, to: the Office of National Statistics (ONS) births and deaths register,
the National Community Child Health Database [NCCHD] [http://www.publichealthwales
observatory.wales.nhs.uk/ncchd], the Patient Episode Database for Wales [http://www.wales.
nhs.uk/document/176173], and CARIS [Congenital Anomaly Register and Information Ser-
vice for Wales] [http://www.caris.wales.nhs.uk/home]. Databases were linked by a trusted
third party [NHS Wales Informatics Service [NWIS]] [http://www.wales.nhs.uk/sitesplus/956/
home].
Population
The study population included all births in Wales after 24 gestational weeks between 1st January
2000 and 31st December 2010, with linked maternal prescription data. Infants were included
where the associated maternal ID could be linked with the primary care dataset (dependent on
the general practice) and the record was complete [27]. We included all infants where the
woman was present in the linked database with primary care prescription information 91 days
before LMP to birth. Information on start of pregnancy was obtained from ultrasound scan
data recorded in the NCCHD for Wales [27]. Infants with congenital anomalies were excluded,
as associations with asthma prescriptions are reported elsewhere [19]. The impact of antidepres-
sants on breastfeeding, premature birth and SGA in this cohort has been reported [28].
Exposure
Prescriptions reflect physicians’ assessment of asthma severity [5, 29], since prescribers adhere
to guidelines [5] that direct monitoring and prescribing. Exposure to “any asthma medicines”
was defined as the woman having been prescribed at least one asthma medicine [ATC code
R03] in the 3 trimesters of pregnancy, defined as 1st day of LMP to birth [15]. Exposure was
grouped, based on 5-digit ATC codes [30] into 10 categories, listed in Table 1. Exposure to
oral corticosteroids was restricted to those co-prescribed other asthma medicines.
Combined LABA and ICS preparations [R03AK] were added to the separate exposure cate-
gories, and not analysed as one group as this would preclude discussion of the disparate bio-
logical effects. We did not analyse exposure to systemic beta2 agonists, cromolyns,
theophylline or anti-cholinergic medicines separately, due to very low prescription rates in this
population (<40 pregnant women exposed to any of these 2004–10) [4].
Outcomes
Prematurity was defined as<37 completed weeks’ gestation, and ‘very premature’ as<32
completed weeks [32].
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Growth centiles were calculated from WHO standards for the UK, and infants below the
10th and 3rd centiles were identified; the latter is defined as 2 standard deviations below the
median or 50th centile [33].
Breastfeeding in this database is defined as ‘any breastfeeding’ (exclusive or combined, pre-
dominantly or partially, with other feeds, including formula milk) as routinely recorded by
health visitors at birth and 6–8 weeks and entered into NCCHD [34]. Data collection is more
complete in some Health Board regions than others [35]. Breastfeeding data were available
from 2004. Breastfeeding at birth may represent intention to breastfeed, rather than actuality:
a high proportion of dyads breastfeeding at birth have discontinued a week later. Therefore,
this measure is downgraded as evidence of successful breastfeeding [36].
Confounding
To minimise confounding by co-exposure, we restricted the dataset by excluding pregnancies
known to be at risk of adverse outcomes [37]. We achieved a relatively homogeneous popula-
tion by excluding from the main analysis infants: 1) with major congenital anomalies; [38] 2)
from multiple pregnancies; 3) stillborn; 4) exposed in the quarter preceding pregnancy or tri-
mester 1 to medicines more closely associated with adverse outcomes than asthma medicines:
Table 1. Exposure classification.
Description Medicine ATC BTS step
Asthma before or during pregnancy Any asthma medicine 1 year before pregnancy or during pregnancy pre4 to
t3
R03 Any
Medicated asthma Any asthma medicines t1-t3 R03 Any
Un-medicated asthma /Prescription
discontinuation














ICS only Inhaled corticosteroids [ICS] as the only asthma medicine in pregnancy
[t1-t3]
R03BA 2 and well
controlled
ICS any Inhaled corticosteroids [ICS] any prescription in pregnancy [t1-t3] R03BA 2 or higher
LABA any Inhaled long-acting beta-2-agonists [LABA] t1-t3 R03AC12,
R03AC13
3 or higher
LKA any Leukotriene receptor antagonists [LKA] t1-t3 R03DC 3 or higher
OCS asthma Oral corticosteroids [OCS] in combination with any asthma medicine [R03]
t1-t3
H02AB + [R03] 5 [most severe]
In the UK, asthma is initially managed with short acting beta2 agonist [SABA] bronchodilators for symptom relief [step 1]. However, if these are needed >twice per
week or >once a week at night or if exacerbations have occurred in the last 2 years, inhaled corticosteroids [ICS] are recommended [step 2]. If these fail to control
symptoms, additional therapy is prescribed, usually long acting beta2 agonists [LABA] or leukotriene antagonists [LKA], but occasionally oral beta2 agonists or
theophylline [step 3]. Oral corticosteroids are prescribed if combinations of these medicines plus high dose ICS fail to control symptoms [step 5] or to manage acute
exacerbations [5, 29]. British Thoracic Society [BTS]5 step 4 is characterised by high dose ICS plus step 3 medicines. We were unable to extract information on doses, so
did not identify doses of oral medicines or step 4 [high dose ICS]: other inhalers are only available in standard doses. The only indications for these medicines is
‘conditions associated with reversible airways obstruction’ [29].
t represents trimester, t1-3 represents the time between 1st day of last menstrual period [LMP] and birth
Pre1-4 represents the 4 quarters preceding pregnancy
Pre1 represents the quarter immediately preceding pregnancy
Medicines were defined by ATC codes, and then matched to version 2 Read codes in the GP database, using reference data provided by NHS Digital Technology
Reference Data Update Distribution [https://isd.digital.nhs.uk/trud3/user/guest/group/0/home] [31].
There were 0 exposures to ATCs R03AC05-7.
https://doi.org/10.1371/journal.pone.0242489.t001
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anti-epileptic drugs [AEDs] [NO3] [39]; coumarins [B01AA], mainly warfarin [40]; insulins
[A10A]58; [41] and 5) whose mothers had any record of: heavy alcohol use and/or substance
misuse [42], (many of these substances are powerful vasoconstrictors). Prevalences were
checked before exclusion (tabulated in Jordan et al 2019, S3 Table).
We did not exclude moderate alcohol use as this is not known to affect perinatal outcomes
[42], and may be inconsistently recorded. To minimize confounding by indication, we inves-
tigated both medicated and unmedicated asthma, as discontinuation of medication in preg-
nancy. We adjusted for socioeconomic status [SES], as Townsend fifths (S1 Table), parity,
smoking [as ‘yes’ or ‘no’], year of birth, and maternal age, grouped [43].
Statistical analysis
We explored associations between prematurity, SGA and breastfeeding and prescription of
asthma medicines 1 year before or during pregnancy, prescription discontinuation during
pregnancy, and individual asthma medicines [Table 1]. For medicines with sufficient numbers
of exposures, and where feasible, data were explored by logistic regression, backwards likeli-
hood ratio [44], with covariates, SES [45], parity, smoking, age, and year of birth [S1 Table],
using SPSS version 25 for windows [46]. For each analysis we compared the exposed with the
unexposed population. We compared outcomes for women with medicated and un-medicated
asthma (S3 Table). Odds ratios, unadjusted and adjusted are reported together with 95% confi-
dence / compatibility intervals. We explored demographic differences between women with
and without breastfeeding data at 6–8 weeks.
Results
We identified 117,717 pregnancies with complete primary care prescription data. We excluded
4401 infants with congenital anomalies [including 582 termination of pregnancy for foetal
anomalies] and 2589 multiples, leaving 110,727 singletons, of whom 390 were stillborn [41
stillborn multiples].
When those exposed to insulin, AEDs or coumarins were excluded, numbers fell to
109,299, reducing to 107,573 available for analysis when those exposed to heavy drinking or
substance misuse were excluded; 105,311 and 38,725 had data on centiles and breastfeeding at
6–8 weeks [Fig 1].
Stillbirth was more prevalent amongst women prescribed asthma medicines than the unex-
posed population [75/13,516, 0.55% vs.431/113,316, 0.38%, OR 1.56, 1.21–2.00], particularly if
medicines had been discontinued throughout pregnancy [27/3850, 0.70%, OR1.91, 1.29–2.82].
Prevalence of deprivation, smoking, substance or alcohol misuse, prescription of insulin and
AEDs was higher amongst women prescribed asthma medicines, with the exception of those
prescribed ICS or ICS only. The prevalence of obesity [BMI>30] was higher amongst women
with asthma, particularly those prescribed corticosteroids. Women discontinuing asthma
medicines were younger, but not more deprived, than those continuing [S1 Table].
Asthma medicines were prescribed to 12,690/107,573 [11.8%] of the cohort before or dur-
ing pregnancy; 3589/12690 [28.3%] received their last prescription before pregnancy, and were
deemed to have ‘discontinued’ [S2 Table]. Most [8413, 92.4%] of the 9101 women prescribed
asthma medicines in pregnancy received SABA, and 3820 [45.4%] of these 8413 received only
SABA. Only 3875/ 9109 (42.6%) women received ICS, and 374 received ICS only. LABA were
prescribed to 465 women and LKA to 89. OCS were prescribed to 519 women co-prescribed
medicines for asthma. Women with breastfeeding data were older than those without [mean
ages 28.48 [6.09] vs. 28.04 [6.04] years, mean difference 0.44 [0.36–0.51], t 11.36, df 79659,
p<0.001], more deprived [mean Townsend score 0.40 [3.24] vs. 0.21 [3.12], mean difference
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0.20 [0.16–0.24], t 9.65, df 77578, p<0.001], and less likely to be primiparous [16095/38725,
41.6% vs. 29388/68848, 42.7% OR 0.96 [0.93–0.98].
Premature birth
Premature birth at<37 or<32 weeks was more prevalent if asthma prescriptions had been
discontinued before pregnancy, when compared with the whole population [aOR 1.22, 1.06–
1.41, and aOR 1.53, 1.11–2.10,]. Any asthma medicine prescription before or during preg-
nancy was not associated with birth at<37 weeks, but was associated with extreme prematu-
rity [aOR 1.33, 1.09–1.61]. Birth at<32 weeks was associated with OCS prescriptions [aOR
2.16, 1.07–4.37]. Birth at<37 and<32 weeks’ gestation was more prevalent if only SABA had
Fig 1. Study flow diagram.
https://doi.org/10.1371/journal.pone.0242489.g001
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been prescribed, but interval estimates included no difference [aOR 1.13, 0.98–1.30 and 1.37,
0.99–1.89]. ICS (any or only) was associated with reduced prevalence of birth at<37 weeks’,
but interval estimates were compatible with no difference [aOR 0.87[0.74–1.02] and 0.64
(0.36–1.15)] [Tables 2 and 3].
SGA
Birth weight <10th centile was associated with any asthma medication before or during preg-
nancy, SABA, ICS, LABA, LKA, and OCS. If prescriptions were discontinued or only ICS
Table 2. Premature birth<37 weeks (n = 107,573).
Exposure Exposed n [%] Unexposed n [%] Unadjusted OR [95% CI Adjusted� OR [95% CI]
Asthma 783/12,690 [6.17] 5374/94,883 [5.66] 1.10 [1.01 to 1.18] 1.08 [0.99 to 1.18]
Medicated asthma 538/9,101 [5.91] 5619/98,472 [5.71] 1.04 [0.95 to 1.14] 1.02 [0.92 to 1.12]
Un-medicated asthma 245/3,589 [6.83] 5912/103,984 [5.69] 1.22 [1.07 to 1.39] 1.22 [1.06 to 1.41]
SABA only 251/3,820 [6.57] 5906/103,753 [5.69] 1.17 [1.02 to 1.33] 1.13 [0.98 to 1.30]
SABA any 506/8,413 [6.01] 5651/99,160 [5.70] 1.06 [0.96 to 1.16] 1.04 [0.94 to 1.15]
ICS only 12/374 [3.21] 6145/107,199 [5.73] 0.55 [0.31 to 0.97] 0.64 [0.36 to 1.15]
ICS any 199/3,875 [5.14] 5958/103,698 [5.75] 0.89 [0.79 to 1.03] 0.87 [0.74 to 1.02]
LABA any 18/465 [3.87] 6139/107,108 [5.73] 0.66 [0.41 to 1.06] 0.60 [0.35 to 1.03]
LKA any <5 /89 6155/107,484 [5.73] OR >1Not significant OR >1Not significant
OCS asthma 30/519 [5.78] 6127/107,054 [5.72] 1.01 [0.70 to 1.46] 0.93 [0.62 to 1.40]
Exclusions from analysis: all anomalies, terminations of pregnancy for foetal anomalies [TOPFA], stillbirths, multiple births [twins, triplets and quadruplets [no higher
multiples in the dataset]], exposure to insulin, anti-epileptic drugs [AEDs] or coumarins in the quarter preceding pregnancy and trimester 1, heavy drinking/substance
misuse [any record]. For each analysis we compared the exposed with the unexposed population.
�adjusted for parity, smoking, year of birth, socio-economic status [SES] as Townsend fifth [quintile], and maternal age as: <20, 20–24, 25–29, 30–34, 35–39, 40–44, 45–
49, 50–54, >54.
Deprivation [Townsend] scores, ranks and fifths are based on geographical area of residence, using Lower Super Output Areas [LSOAs] defined by residential
postcodes. This measure of material deprivation is calculated from rates of unemployment, vehicle ownership, home ownership, and overcrowding [Townsend et al
1988 [45].
Exposures were not mutually exclusive. All those exposed to OCS, LABA and LKA were exposed to other asthma medicine5.
Abbreviations and definitions are listed in Table 1.
OR odds ratio, CI confidence intervals.
The prevalence of premature birth reported here is congruent with WHO data31
https://doi.org/10.1371/journal.pone.0242489.t002
Table 3. Premature birth<32 weeks (n = 107,573).
Exposure Exposed n [%] Unexposed n [%] unadjusted OR [95% CI] adjusted� OR [95% CI]
Asthma 131/ 12,690 [1.03] 802/ 94,883 [0.85] 1.22 [1.02 to 1.47] 1.33 [1.09 to 1.61]
Medicated asthma 88/9,101 [0.97] 845/98,472 [0.86] 1.13 [0.91 to 1.41] 1.21 [0.96 to 1.53]
Un-medicated asthma 43/3,589 [1.20] 890/103,984 [0.86] 1.40 [1.03 to 1.91] 1.53 [1.11 to 2.10]
SABA only 43/3,820 [1.13] 890/103,753 [0.86] 1.32 [0.97 to 1.79] 1.37 [0.99 to 1.89]
SABA any 84/8,413 [1.00] 849/99,160 [0.86] 1.17 [0.93 to 1.46] 1.26 [0.99 to 1.59]
ICS only <5/374 929-932/107,199 OR <1Not significant OR<1 Not significant
ICS any 30/3,875 [0.77] 903/103,698 [0.87] 0.89 [0.62 to 1.28] 0.92 [0.63 to 1.35]
LABA any <5 /465 929/107,108 OR <1Not significant OR >1Not significant
LKA any <5 /89 932/107,484 OR >1Not significant OR >1Not significant
OCS and asthma 9/519 [1.73] 924/107,054 [0.86] 2.03 [1.05 to 3.93] 2.16 [1.07 to 4.37]
Exclusions, definitions, adjustments and abbreviations as in Table 2.
https://doi.org/10.1371/journal.pone.0242489.t003
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prescribed, odds ratios were similar, but interval estimates included no difference. Lower odds
ratios were seen where SABA was prescribed alone. LABA and LKA were associated with birth
weight <3rd centile, but numbers were low [Tables 4, 5].
Breastfeeding
Prevalence of breastfeeding at 6–8 weeks was some 3% lower following prescriptions before or
during pregnancy or prescription discontinuation, but interval estimates in adjusted analyses
included no difference. Association with any SABA or any ICS in unadjusted analyses dimin-
ished when smoking, maternal age and SES were accounted [Table 6].
In all analyses, smoking and SES were significant in the final models. Maternal age pre-
dicted breastfeeding, but not preterm delivery or SGA.
Discussion
Prescription of asthma medicines during pregnancy or in the preceding year was associated
with birth before 32 weeks’ gestation and at<10th centile, and exclusive formula feeding at
Table 4. Small for Gestational Age [SGA]<10th centile (n = 105,331).
Exposure Exposed n [%] Unexposed n [%] unadjusted OR [95% CI] adjusted� OR [95% CI]
Asthma 1192/12,413 [9.60] 7965/92,918 [8.58] 1.13 [1.06 to 1.21] 1.10 [1.03 to 1.18]
Medicated asthma 845/8,904 [9.50] 8312/96,427 [8.62] 1.11 [1.03 to 1.20] 1.09 [1.01 to 1.19]
Un-medicated asthma 347/3,509 [9.89] 8810/101,822 [8.65] 1.16 [1.04 to 1.30] 1.10 [0.98 to 1.25]
SABA only 343/3,739 [9.17] 8814/101,592 [8.68] 1.06 [0.95 to 1.19] 1.02 [0.90 to 1.15]
SABA any 785/8,225 [9.54] 8372/97,106 [8.62] 1.12 [1.04 to 1.21] 1.09 [1.01 to 1.19]
ICS only 35/370 [9.36] 9122/104,961 [8.69] 1.10 [0.78 to 1.56] 1.16 [0.80 to 1.69]
ICS any 380/3,786 [10.04] 8777/101,545 [8.64] 1.18 [1.06 to 1.31] 1.16 [1.03 to 1.30]
LABA any 57/457 [12.47] 9100/104,874 [8.68] 1.50 [1.14 to 1.98] 1.75 [1.31 to 2.34]
LKA any 12/87 [13.48] 9145/105,244 [8.69] 1.68 [0.91 to 3.10] 1.93 [1.01 to 3.69]
OCS and asthma 58/510 [11.37] 9099/104,821 [8.68] 1.35 [1.03 to 1.78] 1.41 [1.05 to 1.90]
Exclusions, definitions, adjustments and abbreviations as in Table 2
%s reported are of those with data.
–Unadjusted OR not significant
https://doi.org/10.1371/journal.pone.0242489.t004
Table 5. Small for Gestational Age [SGA]<3rd centile (n = 105,331).
Exposure Exposed n [%] Unexposed n [%] unadjusted OR [95% CI] adjusted� OR [95% CI]
Asthma 260/12,413 [2.09] 1707/92,918 [1.84] 1.14 [1.00 to 1.30] 1.07 [0.92 to 1.23]
Medicated asthma 179/8,904 [2.01] 1788/96,427 [1.85] 1.09 [0.93 to 1.26] 1.03 [0.87 to 1.22]
Un-medicated asthma 81/3,509 [2.31] 1886/101,822 [1.85] 1.25 [1.00 to 1.57] 1.14 [0.89 to 1.46]
SABA only 78/3,739 [2.09] 1889/101,592 [1.86] 1.13 [0.89 to 1.41] 1.02 [0.80 to 1.31]
SABA any 164/8,225 [1.99] 1803/97,106 [1.86] 1.08 [0.92 to 1.26] 1.02 [0.86 to 1.21]
ICS only 5-9/(370–373) [<5]�� 1958-1962/104,961 [1.87] 1.16 [0.58 to 2.34] 1.22 [0.57 to 2.59]
ICS any 78/3,786 [2.06] 1889/101,545 [1.86] 1.11 [0.88 to 1.40] 1.09 [0.85 to 1.39]
LABA any 13/457 [2.84] 1954/104,874 [1.86] 1.54 [0.89 to 2.68] 1.84 [1.05 to 3.22]
LKA any 5-9/(85–88) [<10]�� 1962/105,244 [1.86] 3.21 [1.30 to 7.94] 3.21 [1.16 to 8.93]
OCS asthma 9/510 [1.76] 1958/104,821 [1.87] 0.94 [0.49 to 1.83] 0.96 [0.48 to 1.29]
Exclusions, definitions, adjustments and abbreviations as in Table 2
��These exact numbers cannot be disclosed, because these exposures are associated with <5 cases where the birth centile is unknown for this exposure.
%s reported are of those with data.
https://doi.org/10.1371/journal.pone.0242489.t005
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6–8 weeks. However, discontinuation of medicines was associated with premature birth [<37
and<32 weeks]; whilst exclusive formula feeding and SGA were more prevalent, interval esti-
mates were compatible with no effect in adjusted models.
Adverse outcomes were more common amongst women treated with OCS, the most
severely asthmatic, but the highest prevalence of premature birth and exclusive formula feed-
ing was amongst those discontinuing prescriptions. ICS prescription appeared to offer some
protection against prematurity. Although SABA-only indicates the least severe asthma [BTS5
stage 1], women prescribed ICS for more persistent symptoms [BTS stage 2] had better out-
comes [12].
Premature birth
The association with premature birth reflects findings of a meta-analysis indicating increased
risks for women diagnosed with asthma [3] or using OCS [47], contradicting earlier studies
[6–8]. We did not confirm that increased risks are confined to those with more severe asthma
[10, 11]. Rather, risks appeared to be increased by prescription discontinuation, which may
worsen symptoms [48, 49]. Preterm birth appeared more likely where only SABA were pre-
scribed, although interval estimates included no difference, supporting recent guidelines no
longer recommending ‘SABA only’ regimens for any asthma [50].
SGA
Intrauterine growth restriction is associated with asthma [8, 9, 51, 52], particularly if severe
[53–55], or symptomatic [7] or accompanied by reduced spirometry parameters [10], congru-
ent with our findings that all asthma medicines, except ICS-only or SABA-only, were associ-
ated with increased prevalence of SGA (<10th centile). Prescription discontinuation increased
the prevalence of SGA, but interval estimates included no difference [55]. SGA is often second-
ary to placental insufficiency, subsequent to vasoconstriction of any aetiology, including pre-
eclampsia, hypoxia [56, 57], smoking, cocaine [58], or, possibly, other sympathomimetics,
such as beta2 agonists. Associations between LABA and birth weight <10th or<3rd centile
and SABA with <10th centile may reflect vasoconstrictor properties [Tables 4, 5]. Associations
with OCS, as elsewhere [7, 47], may reflect hypoxic asthma exacerbations or severity or the
pharmacodynamics of corticosteroids. The associations between LABA and LKA and SGA
<3rd centile may be confounded by asthma severity. These data might support a dose-
Table 6. Breastfeeding at 6–8 weeks (n = 38,725).
Exposure Exposed n [%] Unexposed n [%] unadjusted OR [95% CI] adjusted� OR [95% CI]
Asthma 1499/4,915 [30.50] 11,294/33,810 [33.40] 0.88 [0.82–0.93] 0.93 [0.87 to 1.01]
Medicated asthma 1086/3,519 [30.86] 11,707/35,206 [33.25] 0.90 [0.83–0.97] 0.94 [0.87 to 1.03]
Un-medicated asthma 413/1,396 [29.58] 12,380/37,329 [33.16] 0.85 [0.75–0.95] 0.92 [0.81 to 1.05]
SABA only 453/1,449 [31.26] 12,340/37,276 [33.10] 0.92 [0.82–1.03] 1.00 [0.88 to 1.14]
SABA any 1006/3,275 [30.72] 11,787/35,450 [33.25] 0.89 [0.82–0.96] 0.95 [0.87 to 1.04]
ICS only 35/113 [30.97] 12,758/38,612 [33.04] 0.91 [0.61–1.36] 0.81 [0.52 to 1.28]
ICS any 423/1,403 [30.15] 12,370/37,322 [33.14] 0.87 [0.78–0.98] 0.91 [0.80 to 1.04]
LABA any 52/163 [31.90] 12,741/38,562 [33.04] 0.95 [0.68–1.32] 0.92 [0.62 to 1.36]
LKA any 19/45 [42.22] 12,774/38,680 [33.02] 1.48 [0.82–2.68] 1.73 [0.91 to 3.30]
OCS asthma 71/234 [30.34] 12,722/38,491 [33.05] 0.88 [0.67–1.17] 0.96 [0.70 to 1.31]
Exclusions, definitions, adjustments and abbreviations as in Table 2
%s reported are of those with data.
https://doi.org/10.1371/journal.pone.0242489.t006
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response vasoconstriction hypothesis, only partly dependent on hypoxia: infants exposed to
more than one medicine, likely associated with more severe asthma, were rather more vulnera-
ble to SGA.
Un-medicated asthma
Many women (28.3%) discontinued their asthma medicines during pregnancy, unlike in Scan-
dinavian cohorts [59, 60]. Un-medicated asthma was associated with premature birth, but the
interval estimates for associations with SGA and exclusive formula feeding included no
difference.
To meet the physiological demands of pregnancy, tidal volume and resting alveolar ventila-
tion increase and expiratory reserve declines [61, 62]. In some women, pulmonary reserve
may be insufficient to meet the increased demands for oxygen, accounting for increases in pre-
scribing of SABA and ICS in trimester 2 [4]. In women with severe asthma, symptoms of
asthma, and attendant risks of hypoxia, may intensify late in trimester 2 or post-partum [62].
In contrast, some women become symptom-free during pregnancy [16]. However, even if
asthma becomes asymptomatic, persistent airway remodelling [basement membrane thicken-
ing] and immunological changes, predictive of subclinical bronchial hyper-responsiveness,
remain [63]. Some women voluntarily suspend medication during pregnancy, opting to toler-
ate symptoms rather than risk harming their unborn children [64]. Any uncontrolled asthma
may cause chronic or intermittent hypoxia and inflammation, which adversely affect both
mother and foetus [62, 63], and may impair foetal development, causing intrauterine growth
restriction, foetal distress, pre-term birth and, occasionally, death: stillbirths were more preva-
lent amongst women discontinuing asthma prescriptions [0.70%] when compared with UK
rates 2000–2010 [0.51–0.58%] [65], and women never prescribed asthma medicines [0.38%]
[S1 Table].
Non-adherence to asthma therapies exacerbates symptoms [5, 66]. Absence of prescriptions
for 9 months indicates withdrawal of therapy, as it is unlikely that stockpiled inhalers would be
sufficient over this length of time. We do not know why women discontinued prescriptions or
whether they experienced respiratory symptoms or they or their healthcare professionals
attributed dyspnea to pregnancy [67] or they remained well themselves, while their foetuses
suffered episodes of hypoxia. Hypoxia stimulates release of placental corticotrophin-releasing
hormone [CRH] and inflammatory cytokines. Placental CRH increases maternal and foetal
cortisol production, which augments placental CRH release via positive feedback mechanisms,
amplifying signals that may culminate in premature birth in ~5% infants [54, 68]. The stron-
gest predictors of premature birth were medicines discontinuation and OCS, supporting the
hypoxic trigger hypothesis. The apparent protection against prematurity afforded by ICS sug-
gests that ICS may have been controlling inflammation and asthma, thereby preventing hyp-
oxia, and consequent CRH release, despite the potential to mimic endogenous corticosteroids.
Only 374 women were using ICS alone, and, since they did not need SABA, their asthma was
probably well controlled, suggesting little risk from hypoxia. Beta2 agonists were formerly pre-
scribed as tocolytics, but here they did not protect against premature birth, indicating that
other factors were over-riding their actions on myometrial receptors.
Breastfeeding
Breastfeeding rates were reduced if asthma medicines had been prescribed before or during
pregnancy, and if prescriptions had been discontinued, but adjusted interval estimates
included no difference [Table 6]. Assurances [5, 28] on the safety of SABA, ICS, most LABA,
and OCS at<40mg per day may have contributed to the absence of a negative effect of
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prescriptions on breastfeeding. Manufacturers advise against breastfeeding while using LKA;
[28, 69] however, it would appear these warnings were discounted.
Beta2 agonists are generally considered safe during lactation [28, 69], although high doses
and oral administration can cause tachycardia and restlessness in the infant [70]. Only small
quantities of inhaled medicines reach the infant, and further work is needed to explore
whether sympathomimetic effects cause sufficient restlessness [70] to impede latching, making
early breastfeeding more difficult and painful or whether the sympathomimetic properties of
beta2 agonists might hinder lacto genesis: [71] either might account for a reduced prevalence
of breastfeeding, which was not seen here when SES, maternal age and smoking were
accounted. Breastfeeding was not adversely affected by LKA and OCS, which are prescribed
for severe asthma. Transfer of ICS to the infant is low [69], but too few women were prescribed
only ICS to assess the impact on breastfeeding.
The breastfeeding rates at 6–8 weeks reported here reflect Wales’s current data (2131/6366,
33.47%) [72]. Contemporary recruited cohorts elsewhere report higher breastfeeding rates
amongst women with asthma, for example, 536/605, 88% at birth, 230/605 38% at 6 months
[73]. Increasing breastfeeding rates in the UK by 0.1% would offer considerable benefit: the
associated small increase in infants’ average IQ gains >£27.8 million in economic productivity
across each annual birth cohort [74], suggesting that the ~3% improvement identified here
would be worthwhile. Breastfeeding support should not end at birth. Mild or moderate asthma
may worsen post-partum: how this, and the associated loss of sleep, affects breastfeeding is
unknown.
Supporting women with asthma
Premature birth, SGA and suboptimal breastfeeding are public health concerns [75]. Extreme
prematurity carries a 6.2% risk of cerebral palsy and a 40% risk of broncho-pulmonary dyspla-
sia, whilst birth before 37 weeks carries a 1% risk of cerebral palsy and 40% risk of cognitive
impairment [76]. Birth weight below the 10th centile is linked to a range of conditions from
neonatal asphyxia to mental health conditions in adulthood [58], changes in brain morphology
[77] and beta cell function [78].
The associations between un-medicated asthma and premature birth support the consensus
that uncontrolled asthma increases the risk of adverse perinatal outcomes subsequent to pre-
mature birth [3], but risks were not confined to severe asthma [5, 79]. Rather, we highlight the
importance of identifying the 28% of women with asthma who completely discontinue medi-
cines, often ICS [80], as being at increased risk of premature birth and exclusive formula feed-
ing; these women were apparently without symptoms sufficiently severe to warrant
prescriptions.
We confirmed associations with SES and smoking [58, 81], but asthma medicines before or
during pregnancy or their discontinuation independently predicted adverse outcomes. Lower
family income and education intensify the impact on families of behavioural and neurodeve-
lopmental sequelae of premature birth [cerebral palsy, cognitive impairment, impaired hearing
or vision] [82], and the concentration of adverse outcomes and asthma prescriptions amongst
the most economically deprived in Wales [83] [S1 and S2 Tables] accentuates the importance
of using these findings to target support.
Prescription patterns, regardless of diagnoses, particularly discontinuation in pregnancy,
offer primary care practitioners a convenient marker to identify pregnancies at increased risk,
analogous to ‘intention to treat’ analyses: pragmatic but of unproven biological certainty.
Alternative markers, such as smoking or socioeconomic deprivation, would not identify
women discontinuing prescriptions [S1 and S2 Tables]. Women with severe illness are usually
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actively managed in specialist clinics in secondary or tertiary care, minimizing risks reported
here: [3] our findings on prescription discontinuation, SABA and ‘SABA-only’ support this.
Although current UK guidelines do not recommend additional surveillance before or during
pregnancy [5] or initiatives to target support to optimize prescription regimens and infant
feeding, ‘at risk’ women [those discontinuing or using SABA or OCS] need extra help. Addi-
tional monitoring by specialist respiratory nurses, in parallel with midwifery care, can improve
asthma control [84], but large studies are needed to assess impact on perinatal outcomes.
Strengths and limitations
Retrospective cohorts, such as ours, have minimal volunteer selection and attrition bias [83]
and no recall bias [24].
Generalisation
The prevalence of asthma prescribing in our cohort reflects that across the UK and USA, but
there is less confidence in generalisation to populations with lower prescription [3, 4], or
higher breastfeeding rates. Coverage was limited to 40% of the population, due to suboptimal
GP participation [27]. Restrictions of our cohort were due to incomplete GP participation and
data, due to practices’ technical failures or women moving to practices not covered by SAIL
[27]. The breastfeeding outcome was further restricted by variations in recording practices
across the seven Health Boards, but there was no self-selection by participants. Had a volunteer
bias been operating, we should have expected to see older, less deprived women over-repre-
sented [83]; this was not the case.
Restricting the dataset by excluding pregnancies exposed to AEDs, insulin, coumarins,
heavy drinking or substance misuse and multiple pregnancies increased internal validity with-
out introducing bias, at the cost of generalisation to these groups [37, 85]. The higher preva-
lence of these exposures amongst women prescribed asthma medicines (S1 Table) would have
caused overestimation of harm attributed to asthma medicines. Rarer co-morbidities were not
excluded. Co-morbid rheumatoid arthritis and inflammatory bowel disease were more likely
amongst women prescribed oral corticosteroids, who would have received specialist care [5].
Detail in the database
We have no information as to whether premature births were spontaneous or induced:
asthma is associated with conditions necessitating preterm induction of labour, such as pre-
eclampsia [54, 86]. Neither population databases nor fieldwork fully capture symptoms, histo-
ries, spirometry, oxygen saturation, or psychosocial stressors. Maternal stress, short and long-
term, increases the risk of pre-term birth [68, 81]. Substance misuse is notoriously difficult to
capture, and may be under-reported; however, it is often persistent. We excluded the most vul-
nerable women [39–42]. The proportion of missing data [35.5% overall, 29.3% in women with
asthma], precluded inclusion of BMI in regression analyses [S1 Table]. Any increased preva-
lence of these predictors of adverse outcomes amongst exposed women would lead to over-
estimation of associations [87]. Paternity and paternal sibships are not recorded, as in many
databases [88], but impact on perinatal outcomes are believed to be modest [89]. We consid-
ered each pregnancy separately, as exposures and covariates (e.g. smoking, deprivation) often
vary between pregnancies. We acknowledge the genetic determinants of perinatal outcomes
[90], but, without information on their association with asthma, are unable to predict how
accounting for this would have affected this study. The database’s timeframe did not allow us
to distinguish women receiving their first ever prescription during pregnancy.
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No data were available on miscarriage and induced terminations. Confining analyses to
otherwise healthy live-born infants introduces a survival / survivorship bias, leaving some
harms unreported, and under-estimating overall harm [87]. This was confirmed by the slightly
higher rates of stillbirth (S1 Table). Congenital anomalies and stillbirths are associated with
SGA and preterm birth [88], and the higher prevalence of congenital anomalies amongst
women exposed to asthma medicines in this cohort is known [19]; therefore, affected infants
were excluded.
We have no data on dispensing or hospital or private prescribing or internet purchasing. It
is unlikely that anyone hospitalized with asthma or consulting privately would not be receiving
prescriptions from primary care practitioners. Abolition of prescription charges in Wales in
2007 reduces the likelihood of private prescriptions and purchasing. Our data predate primary
care prescription of monoclonal antibodies for severe eosinophilic asthma persisting despite
oral corticosteroid therapy. Manufacturers advise avoiding these medicines in pregnancy [28];
therefore, population databases may be unable to describe their safety in pregnancy for some
time. Too few women were prescribed LABA (465) or LKA (89) or ICS only (362) to draw con-
clusions relating to extreme prematurity or SGA, but findings are congruent with other studies
[86].
We do not know whether any women had been over- or mis-diagnosed with asthma [91],
or if any withdrawal symptoms arose [92–95] and remained un-medicated. Without data on
medicines purchased without prescription, we could not explore the hypothesis that ‘asthma
with hay fever’ is a stronger predictor of premature birth than non-atopic asthma [86]. Simi-
larly, paucity of testing for exhaled nitric oxide, known not to improve outcomes [14], made it
impossible to ascribe eosinophilic or allergic aetiology to the diagnosis.
Adherence to prescribed regimens cannot be ascertained from prescription or dispensing
data. 30–50% of patients prescribed long-term treatment do not take medicines as recom-
mended [92], and we also have no information on inhaler techniques or any stockpiling or
sharing of inhalers. (Excluding substance misusers reduces the latter possibility.) Non-adher-
ence dilutes the impact of medicines on outcomes; however, since discontinuation was associ-
ated with harm, unreported discontinuation in those receiving prescriptions might lead to an
over-estimation of harms attributed to prescriptions.
Multiple testing
We acknowledge the hazards of multiple testing, without correction. Our independent (pre-
dictor) variables are highly correlated. This makes standard adjustments, such as the Bonfer-
roni method, unduly conservative, risking false negatives [96]. Observation studies are limited
by unmeasured confounding, and the impossibility of including all contextual variables [97,
98]. Our findings are consistent with biological plausibility and the literature.
Confounding and effect mediation
For most adverse outcomes, retrospective analysis yields lower odds or risk ratios than pro-
spective studies [93]. However, this is not true of cohorts examining asthma in pregnancy.
This might be interpreted as prospective cohort studies offering enhanced opportunities to
control asthma, particularly to optimize prophylaxis with ICS [3], supported here by sugges-
tions of improved outcomes with ICS prescriptions.
In evaluating the impact of medicines using population databases, it is rarely possible to
avoid residual confounding by indication and severity of indication without randomisation
[99, 100]. Prescriptions are sometimes taken as proxies for diagnoses [101], as diagnoses are
not always recorded in healthcare databases, and these medicines have no other indications in
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the UK [28]. Since the risks of poorly controlled asthma outweigh the risks of harm to the foe-
tus, only the mildest maternal asthma is un-medicated on medical advice [5, 50], but we do
not know whether continuing prescriptions indicated recurrent symptoms or a propensity to
compliance. We acknowledge the difficulties of disentangling the effects of asthma from its
management. Nevertheless, these findings should alert practitioners to the need for targeted
care preconception, and during pregnancy and lactation.
Implications: Support before, during and after pregnancy
The clinical consequences of premature birth, including cerebral palsy and cognitive
impairment [76], increase the importance of the modest [ORs<2] associations identified.
Women discontinuing prescriptions were probably relatively unaffected by symptoms, whilst
an additional ~1% of their infants were born preterm: discontinuation may have increased the
risk of hypoxia [and hence premature birth]. Taken with lower breastfeeding rates, these find-
ings identify unmet needs amongst women discontinuing prescriptions, and militate against
medication reduction in pregnancy [102]. Reduced risks with ICS suggest that increased moni-
toring, targeted support and active asthma management [3, 50] are needed before, during and
after pregnancy. Programming primary care electronic records to alert professionals to contact
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52. Rejnö G, Lundholm C, Larsson K, Larsson H, Lichtenstein P, D’Onofrio BM, et al. Adverse Pregnancy
Outcomes in Asthmatic Women: A Population-Based Family Design Study. J Allergy Clin Immunol
Pract. 2018 May -Jun; 6(3):916–922.e6. Epub 2017 Oct 4. https://doi.org/10.1016/j.jaip.2017.07.036
PMID: 28988783.
PLOS ONE Asthma medicines, discontinuation and perinatal outcomes, including breastfeeding
PLOS ONE | https://doi.org/10.1371/journal.pone.0242489 December 9, 2020 17 / 20
53. Wadhwa PD, Entringer S, Buss C, Lu MC. The contribution of maternal stress to preterm birth: issues
and considerations. Clin Perinatol. 2011 Sep; 38[3]:351–84. https://doi.org/10.1016/j.clp.2011.06.007
PMID: 21890014
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